Although elevated PSA levels resulting from architectural distortion and low levels due to impaired PSA secretion by tumor cells explain some of these discrepancies [5, 6], concerns about the reliability of PSA for monitoring disease progression provide a strong rationale for identifying alternative markers of disease progression, particularly those that are therapeutically targetable. This evidence concerns the gene KLK3 and neoplasm.